Navigation Links
InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
Date:5/5/2011

, thereby preventing enough oxygen from getting to the heart's muscle. As a result, part of the heart muscle dies and becomes permanently inactive.

About MGuard™ Coronary

MGuard™ presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard™ stent provides outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).

About InspireMD Inc.

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD is traded on the over-the-counter bulletin board (OTC BB) under the ticker "NSPR".

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new produ
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InspireMD Boosts MGuard Production Capacity
2. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
3. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
4. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
5. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
6. Express Scripts Announces Intention to Commence a Debt Offering
7. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
8. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
9. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
10. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
11. Unilife Commences Initial Production of Unifill Prefilled Syringe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... of the gastro-intestinal tract has long been considered to ... the Sahlgrenska Academy have used refined microscopic techniques that ... surface of the gastro-intestinal tract is only as large ... , The digestive tract, which passes from the mouth ... a length of about 5 meters in a normal ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... in the popular Swedish children,s TV show Bolibompa, ... A new study from the University of Gothenburg ... programmes as well as the link between young ... , Steingerdur Olafsdottir,s doctoral thesis focuses on the ... TV show Bolibompa. Healthy foods dominated in the ...
(Date:4/23/2014)... from the Cancer Science Institute of Singapore (CSI Singapore) ... cancer specific stem cell which causes gastric cancer. This ... for the treatment of this disease and other types ... Chan Shing Leng, Research Assistant Professor at CSI Singapore, ... of a cell surface protein, CD44v8-10, marks gastric cancer ...
(Date:4/23/2014)... published in the journal Oncotarget , explored ... appearances or their own DNA signatures within the ... to design effective, targeted treatment strategies. , Firstly ... mutation and either the KRAS or BRAF mutation. ... the EGFR gene mutation have that specific mutation ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
... recommended treatments, study found , FRIDAY, May 28 (HealthDay ... designed to review current research and guidelines, doctors made ... patients with high blood pressure, a new study reports. ... reflected in the practices of community physicians remains a ...
... Chase Cancer Center investigators find that pancreatic cancer patients who ... patients without circulating tumor cells. Additionally, the team has uncovered ... and some may predict worse outcomes than others. Benjamin ... will present the study at the 46th Annual Meeting of ...
... the final details on how two stroke-prevention procedures are safe ... stroke, though their effectiveness does vary by age, say researchers ... Public Health in collaboration with other North American stroke investigators. ... Journal of Medicine (NEJM) May 26, the researchers say ...
... ... range of crystalens to benfit the patients. , ... (Vocus) -- Dr. Khanna and crystal lens have had a symbiotic relationship ... has especially been helpful in people who have undergone radial RK or macular degeneration. ...
... to be self-centered, competitive, U.S. research shows , FRIDAY, May ... reveals that American college students are not quite as empathetic ... drop in empathy after the year 2000," co-author Sara Konrath, ... Research, said in a news release. "College kids today are ...
... brain, still befuddles patients and researchers, , FRIDAY, May 28 ... be a lifeline to the future. And more aggressive, high-dose ... there,s a downside, too: Chemotherapy is linked to a mental ... dismissed as "all in your head," but that,s no longer ...
Cached Medicine News:Health News:Putting New Medical Guidelines Into Practice Often Difficult 2Health News:Circulating tumor cells correlate with poorer survival in pancreatic cancer patients 2Health News:Age is a factor in choosing between two comparable stroke-prevention procedures 2Health News:Khannna Institute to offer Crystalens in Quarter Diopter Steps 2Health News:Today's College Students More Likely to Lack Empathy 2Health News:Making Your Way Through the Fog of Chemotherapy 2Health News:Making Your Way Through the Fog of Chemotherapy 3
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: